Loading insider details...
Beta
Latest Form 4 (Jun 4, 2026): Grant/Award of 9,000 KLRS shares.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Jun 4, 2026 | Kalaris Therapeutics, Inc. (KLRS) | Grant/Award | 9,000 | n/a |
| Apr 11, 2025 | Kalaris Therapeutics, Inc. (KLRS) | Grant/Award | 18,000 | n/a |
| Mar 18, 2025 | Kalaris Therapeutics, Inc. (KLRS) | Grant/Award | 19,484 | n/a |
| Jun 25, 2024 | EyePoint Pharmaceuticals, Inc. (EYPT) | Exercise/Conversion | 2,000 | n/a |
| Jan 10, 2024 | EyePoint Pharmaceuticals, Inc. (EYPT) | Grant/Award | 25,014 | n/a |
| Jun 26, 2023 | EyePoint Pharmaceuticals, Inc. (EYPT) | Exercise/Conversion | 2,000 | n/a |
| Jun 22, 2023 | EyePoint Pharmaceuticals, Inc. (EYPT) | Grant/Award | 26,100 | n/a |
| Jun 27, 2022 | EyePoint Pharmaceuticals, Inc. (EYPT) | Grant/Award | 6,000 | n/a |